Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sebastian, Michael
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis	Recruiting	3	1300	Europe, Canada, Japan, US, RoW	TAK-279	Takeda	Plaque Psoriasis	05/26	05/26
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment	Active, not recruiting	3	693	Europe, Canada, Japan, US, RoW	TAK-279, Placebo, Apremilast	Takeda	Plaque Psoriasis	08/25	04/26
NCT05863104 / 2022-000922-46: Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis	Completed	2	44	Europe	Glycopyrronium Bromide (GPB) Cream	Dr. August Wolff GmbH & Co. KG Arzneimittel, Dr. August Wolff GmbH & Co. KG Arzneimittel	Primary Axillary Hyperhidrosis	03/24	03/24
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Recruiting	2	350	Europe, Canada, US, RoW	Eltrekibart, LY3041658, Placebo	Eli Lilly and Company	Hidradenitis Suppurativa	08/25	07/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sebastian, Michael
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis	Recruiting	3	1300	Europe, Canada, Japan, US, RoW	TAK-279	Takeda	Plaque Psoriasis	05/26	05/26
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment	Active, not recruiting	3	693	Europe, Canada, Japan, US, RoW	TAK-279, Placebo, Apremilast	Takeda	Plaque Psoriasis	08/25	04/26
NCT05863104 / 2022-000922-46: Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis	Completed	2	44	Europe	Glycopyrronium Bromide (GPB) Cream	Dr. August Wolff GmbH & Co. KG Arzneimittel, Dr. August Wolff GmbH & Co. KG Arzneimittel	Primary Axillary Hyperhidrosis	03/24	03/24
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Recruiting	2	350	Europe, Canada, US, RoW	Eltrekibart, LY3041658, Placebo	Eli Lilly and Company	Hidradenitis Suppurativa	08/25	07/26